Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman Investigating

SAN FRANCISCO, June 23, 2026 (GLOBE NEWSWIRE) -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.

GlobeNewsWire • 11 hours ago

Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®

TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Right® brand and certain other brands.

GlobeNewsWire • Jun 15, 2026

Why Is Prestige Consumer Healthcare (PBH) Up 3.6% Since Last Earnings Report?

Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jun 11, 2026

PBH Investors Have Opportunity to Join Prestige Consumer Healthcare Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PRNewsWire • Jun 11, 2026

Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference

TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:

GlobeNewsWire • Jun 5, 2026

Is the Options Market Predicting a Spike in Prestige Consumer Stock?

Investors need to pay close attention to PBH stock based on the movements in the options market lately.

Zacks Investment Research • Jun 1, 2026

Protect Your Investment: Contact Levi & Korsinsky About the Prestige Consumer Healthcare Inc. (PBH) Investigation

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) ("Prestige Consumer Healthcare Inc.") concerning potential violations of the federal securities laws. During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4.

Newsfile Corp • May 25, 2026

Prestige Consumer Healthcare, Inc. (PBH) Securities Fraud Investigation - Levi & Korsinsky

Prestige Consumer Healthcare shares fell sharply after Q4 earnings missed consensus estimates -- adjusted EPS came in at $1.23 versus the $1.39 expected, driven by unresolved supply-chain constraints management had assured investors were improving. NEW YORK, May 22, 2026 /PRNewswire/ -- Prestige Consumer Healthcare, Inc. (NYSE: PBH) investors suffered significant losses when the stock dropped after the Company reported Q4 fiscal 2026 earnings well below expectations, with adjusted EPS of $1.23 versus the $1.39 consensus estimate and revenue of $281.6 million falling short of forecasts.

PRNewsWire • May 22, 2026

Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PRESTIGE CONSUMER HEALTHCARE (PBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 13, 2026, Prestige Consumer annou.

Business Wire • May 22, 2026